

Hepatitis D Market - A Global and Regional Analysis: Focus on Treatment Type, Diagnostic Method, and Region - Analysis and Forecast, 2025-2035

<https://marketpublishers.com/r/H9F829090A7AEN.html>

Date: June 2026

Pages: 0

Price: US\$ 4,900.00 (Single User License)

ID: H9F829090A7AEN

Abstracts

Hard copy option is available on any of the options above at an additional charge of \$500. Please email us at order@marketpublishers.com with your request.

This report will be delivered in 7-10 working days.

Global Hepatitis D Market, Analysis and Forecast: 2025-2035

Hepatitis D is a rare, serious, liver disease caused by the hepatitis D virus (HDV), which can only infect individuals who are already infected with the hepatitis B virus (HBV). The virus causes significant liver damage, leading to symptoms such as fatigue, jaundice, abdominal pain, and in severe cases, cirrhosis or liver failure. Hepatitis D is primarily transmitted through contact with infected blood, and its prevalence is high in regions with a high burden of HBV, such as sub-Saharan Africa, Eastern Europe, and parts of Asia. Diagnosis of hepatitis D is often made through serological testing for HDV antibodies and HDV RNA levels. Treatment for hepatitis D includes interferon-based therapies, antiviral agents, and emerging therapies targeting HDV replication. The market for hepatitis D treatments is growing due to advancements in diagnostic technologies, the development of more effective therapies, and the increasing recognition of the disease as a major cause of chronic liver disease.

The hepatitis D market is primarily driven by the rising diagnosis rates, which have been facilitated by advancements in diagnostic technologies such as nucleic acid testing and serological assays. The growing availability of more precise and early detection methods has enabled earlier intervention, which significantly improves patient outcomes and reduces the risk of liver complications. Furthermore, the increasing awareness

among healthcare professionals and patients, along with an expanding global healthcare infrastructure, is driving the demand for effective therapies. The approval and introduction of novel therapies, including bulevirtide and other antiviral agents, are accelerating the expansion of treatment options, providing more targeted and effective solutions for managing hepatitis D infections. Research investments are also contributing to the development of new therapies aimed at targeting HDV replication and improving patient outcomes.

The hepatitis D market faces several challenges, including the high cost of treatment, which can limit patient access, particularly in low- and middle-income regions. Novel treatments are expensive, and while they are effective, their cost remains a barrier for many patients. Additionally, the rarity of hepatitis D means that expertise and experience in managing the disease are limited, which can lead to delayed diagnosis and suboptimal treatment outcomes. The complexity of the disease, particularly its co-infection with hepatitis B, requires a multidisciplinary approach to treatment, further complicating disease management. Regulatory hurdles, such as long approval timelines for new therapies, can also delay patient access to potentially life-saving treatments.

Recent advancements in hepatitis D treatment have introduced new therapeutic options, such as bulevirtide, which effectively inhibits HDV replication. Other emerging therapies are focusing on targeting viral entry and other aspects of the viral lifecycle. Additionally, research into RNA-based therapies, such as RNA interference and gene therapy, is showing promise in offering long-term solutions for hepatitis D. These therapies aim to address the underlying causes of the disease, potentially providing a cure for patients with chronic HDV infections. Ongoing research into liver transplantation and other novel treatments also holds promise for patients with severe liver damage caused by hepatitis D.

The competitive landscape in the hepatitis D market is evolving, with key players such as Gilead Sciences, GSK plc, Janssen Pharmaceuticals and other pharmaceutical companies working on developing new treatments. Several emerging biotech companies are focusing on developing next-generation therapies, including antiviral agents, RNA-based treatments, and gene therapies, with the potential to address unmet needs in the treatment of hepatitis D. Collaborations between pharmaceutical companies, research institutions, and healthcare providers are becoming more common, with a shared focus on advancing personalized medicine and improving long-term outcomes for hepatitis D patients.

Market Segmentation:

Segmentation 1: by Treatment Type

Antiviral Medications

Immunotherapies

Combination Therapies

Segmentation 2: by Diagnostic Methods

Blood Tests

Imaging Techniques

Segmentation 3: by Region

North America

Europe

Asia-Pacific

Rest-of-the-World

The global hepatitis D market is experiencing steady growth, driven by several key factors. Firstly, the increasing diagnosis rates of hepatitis D, particularly in regions with a high prevalence of hepatitis B virus (HBV) infections, have led to a greater demand for effective treatment solutions. Secondly, advancements in diagnostic technologies, including improved genetic testing, serological assays, and nucleic acid testing, have enabled earlier and more accurate detection of hepatitis D, leading to better patient outcomes and enhanced disease management. Thirdly, the approval and introduction of novel therapies, such as bulevirtide and antiviral agents targeting HDV replication, have expanded treatment options, offering more targeted and effective solutions for managing chronic hepatitis D. Additionally, rising awareness among healthcare professionals and patients about the risks associated with co-infection of HBV and HDV

has led to more diagnoses, which further increases the need for specialized therapies. Furthermore, the growing investment in research and development, supported by both public and private sectors, is accelerating the discovery of new antiviral therapies and biomarkers, contributing to the ongoing market growth.

Contents

Executive Summary
Scope and Definition
Market/Product Definition
Inclusion and Exclusion
Key Questions Answered
Analysis and Forecast Note

1. GLOBAL HEPATITIS D MARKET: INDUSTRY ANALYSIS

1.1 Market Overview and Ecosystem
1.2 Epidemiological Analysis
1.3 Key Market Trends
 1.3.1 Impact Analysis
1.4 Regulatory Landscape
1.5 Pipeline Analysis
1.6 Market Dynamics
 1.6.1 Overview
 1.6.2 Market Drivers
 1.6.3 Market Restraints
 1.6.4 Market Opportunities

2. GLOBAL HEPATITIS D MARKET (BY TREATMENT TYPE), VALUE (\$MILLION), 2023-2035

2.1 Antiviral Medications
2.2 Immunotherapies
2.3 Combination Therapies

3. GLOBAL HEPATITIS D MARKET (BY DIAGNOSTIC METHODS), VALUE (\$MILLION), 2023-2035

3.1 Blood Tests
3.2 Imaging Techniques

4. GLOBAL HEPATITIS D MARKET (BY REGION), VALUE (\$MILLION), 2023-2035

4.1 North America

- 4.1.1 Market Dynamics
- 4.1.2 Market Sizing and Forecast
- 4.1.3 North America Hepatitis D Market, by Country (\$Million), 2023-2035
 - 4.1.3.1 U.S.
 - 4.1.3.2 Canada
- 4.2 Europe
 - 4.2.1 Market Dynamics
 - 4.2.2 Market Sizing and Forecast
 - 4.2.3 Europe Hepatitis D Market, by Country (\$Million), 2023-2035
 - 4.2.3.1 U.K.
 - 4.2.3.2 France
 - 4.2.3.3 Germany
 - 4.2.3.4 Italy
 - 4.2.3.5 Spain
 - 4.2.3.6 Rest-of-Europe
- 4.3 Asia-Pacific
 - 4.3.1 Market Dynamics
 - 4.3.2 Market Sizing and Forecast
 - 4.3.3 Asia-Pacific Hepatitis D Market, by Country (\$Million), 2023-2035
 - 4.3.3.1 Japan
 - 4.3.3.2 China
 - 4.3.3.3 India
 - 4.3.3.4 Australia
 - 4.3.3.5 South Korea
 - 4.3.3.6 Rest-of-Asia-Pacific
- 4.4 Rest-of-the-World
 - 4.4.1 Market Dynamics
 - 4.4.2 Market Sizing and Forecast
 - 4.4.3 Rest-of-the-World Hepatitis D Market, by Country (\$Million), 2023-2035
 - 4.4.3.1 Latin America
 - 4.4.3.2 Middle East and Africa

5. COMPETITIVE LANDSCAPE AND COMPANY PROFILES

- 5.1 Competitive Landscape
 - 5.1.1 Mergers and Acquisitions
 - 5.1.2 Partnership, Alliances and Business Expansion
 - 5.1.3 New Offerings
 - 5.1.4 Regulatory Activities

5.1.5 Funding Activities

5.2 Company Profiles

5.2.1 Antios Therapeutics

5.2.1.1 Overview

5.2.1.2 Top Products / Product Portfolio

5.2.1.3 Top Competitors

5.2.1.4 Target Customers/End-Users

5.2.1.5 Key Personnel

5.2.1.6 Analyst View

5.2.2 Aurobindo Pharma Limited

5.2.2.1 Overview

5.2.2.2 Top Products / Product Portfolio

5.2.2.3 Top Competitors

5.2.2.4 Target Customers/End-Users

5.2.2.5 Key Personnel

5.2.2.6 Analyst View

5.2.3 Eiger Biopharmaceuticals

5.2.3.1 Overview

5.2.3.2 Top Products / Product Portfolio

5.2.3.3 Top Competitors

5.2.3.4 Target Customers/End-Users

5.2.3.5 Key Personnel

5.2.3.6 Analyst View

5.2.4 F. Hoffmann-La Roche Ltd

5.2.4.1 Overview

5.2.4.2 Top Products / Product Portfolio

5.2.4.3 Top Competitors

5.2.4.4 Target Customers/End-Users

5.2.4.5 Key Personnel

5.2.4.6 Analyst View

5.2.5 Gilead Sciences

5.2.5.1 Overview

5.2.5.2 Top Products / Product Portfolio

5.2.5.3 Top Competitors

5.2.5.4 Target Customers/End-Users

5.2.5.5 Key Personnel

5.2.5.6 Analyst View

5.2.6 GSK plc

5.2.6.1 Overview

- 5.2.6.2 Top Products / Product Portfolio
- 5.2.6.3 Top Competitors
- 5.2.6.4 Target Customers/End-Users
- 5.2.6.5 Key Personnel
- 5.2.6.6 Analyst View
- 5.2.7 Janssen Pharmaceuticals
 - 5.2.7.1 Overview
 - 5.2.7.2 Top Products / Product Portfolio
 - 5.2.7.3 Top Competitors
 - 5.2.7.4 Target Customers/End-Users
 - 5.2.7.5 Key Personnel
 - 5.2.7.6 Analyst View
- 5.2.8 Merck & Co., Inc.
 - 5.2.8.1 Overview
 - 5.2.8.2 Top Products / Product Portfolio
 - 5.2.8.3 Top Competitors
 - 5.2.8.4 Target Customers/End-Users
 - 5.2.8.5 Key Personnel
 - 5.2.8.6 Analyst View
- 5.2.9 Mylan N.V.
 - 5.2.9.1 Overview
 - 5.2.9.2 Top Products / Product Portfolio
 - 5.2.9.3 Top Competitors
 - 5.2.9.4 Target Customers/End-Users
 - 5.2.9.5 Key Personnel
 - 5.2.9.6 Analyst View
- 5.2.10 Replicor
 - 5.2.10.1 Overview
 - 5.2.10.2 Top Products / Product Portfolio
 - 5.2.10.3 Top Competitors
 - 5.2.10.4 Target Customers/End-Users
 - 5.2.10.5 Key Personnel
 - 5.2.10.6 Analyst View
- 5.2.11 Others

6. RESEARCH METHODOLOGY

List Of Figures

LIST OF FIGURES

Figure: Global Hepatitis D Market Coverage

Figure: Global Hepatitis D Market Key Trends, Impact Analysis, 2023-2035

List Of Tables

LIST OF TABLES

Table: Global Hepatitis D Market (by Treatment Type), \$Million, 2023-2035

Table: Global Hepatitis D Market (by Diagnostic Method), \$Million, 2023-2035

Table: Global Hepatitis D Market (by Region), \$Million, 2023-2035

I would like to order

Product name: Hepatitis D Market - A Global and Regional Analysis: Focus on Treatment Type, Diagnostic Method, and Region - Analysis and Forecast, 2025-2035

Product link: <https://marketpublishers.com/r/H9F829090A7AEN.html>

Price: US\$ 4,900.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/H9F829090A7AEN.html>